What are the European Respiratory Society (ERS) guidelines for long-term mucoactive treatment of bronchiectasis?

Updated: Jul 23, 2019
  • Author: Ethan E Emmons, MD; Chief Editor: Zab Mosenifar, MD, FACP, FCCP  more...
  • Print
Answer

Long-term mucoactive treatment (≥3 mo) is suggested in adult patients with bronchiectasis (1) who have difficulty in expectorating sputum and have a poor quality of life and (2) where standard airway clearance techniques have failed to control symptoms. Recombinant human DNase is not recommended in adult patients with bronchiectasis.


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!